Printer Friendly

STADA orders Enzymatica's ColdZyme Mouth spray for German, Belgian and Austrian markets.

M2 PHARMA-June 14, 2017-STADA orders Enzymatica's ColdZyme Mouth spray for German, Belgian and Austrian markets


German global pharmaceutical company STADA Arzneimittel AG (ETR: SAZ) has ordered Enzymatica's (STO:ENZY) cold product ColdZyme Mouth spray for the German, Belgian and Austrian markets in preparation for the common cold season after the summer. According to an announcement published by the company on Wednesday, it is Enzymatica's largest order to date and is worth around SEK12m.

The order comes as the result of an ongoing cooperation agreement with Enzymatica that STADA reached in February 2017. The agreement stipulates that STADA be granted exclusive rights to sell, market and distribute ColdZyme in Germany, the largest market for OTC products in Europe, in addition to Belgium and Austria.

"We are now beginning to see the results of our efforts to sign agreements with international distributors for the major OTC markets," said Fredrik Lindberg, CEO of Enzymatica. "The order is the largest in Enzymatica's history and is worth much more than the entire sales of SEK9.6m for the first quarter this year."

Enzymatica expects the order to boost the company's third quarter sales.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUGE
Date:Jun 14, 2017
Previous Article:Celltrion Healthcare reveals data supporting efficacy and safety of Truxima in advanced follicular lymphoma and rheumatoid arthritis.
Next Article:GenSight Biologics reports 'promising' clinical trial results for GS010.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters